PTAB Shoots Down Pfizer's Bid To Review Avastin Patent
The Patent Trial and Appeal Board has turned down Pfizer Inc.'s challenge to a patent covering Genentech Inc.'s blockbuster cancer treatment Avastin, finding the challenger couldn't prove the patent shouldn't have...To view the full article, register now.
Already a subscriber? Click here to view full article